Antibiotics Should Be One Step On FDA’s “Critical Path,” Lilly VP Cassell Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The therapeutic category is ideal for FDA’s drug development initiative because antibiotics do not pose antitrust concerns and NIH has allocated $1.7 bil. for research in the area of anti-infectives, the Lilly exec asserts.